GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (LTS:0VGI) » Definitions » Cyclically Adjusted Book per Share

TG Therapeutics (LTS:0VGI) Cyclically Adjusted Book per Share : $1.38 (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is TG Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

TG Therapeutics's adjusted book value per share for the three months ended in Mar. 2025 was $1.500. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.38 for the trailing ten years ended in Mar. 2025.

During the past 12 months, TG Therapeutics's average Cyclically Adjusted Book Growth Rate was -4.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of TG Therapeutics was 74.10% per year. The lowest was -52.50% per year. And the median was -13.40% per year.

As of today (2025-05-29), TG Therapeutics's current stock price is $37.50. TG Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $1.38. TG Therapeutics's Cyclically Adjusted PB Ratio of today is 27.17.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of TG Therapeutics was 30.56. The lowest was 1.52. And the median was 10.68.


TG Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for TG Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Cyclically Adjusted Book per Share Chart

TG Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.04 1.49 1.46 1.52 1.48

TG Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 1.49 1.51 1.48 1.38

Competitive Comparison of TG Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, TG Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

TG Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TG Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.5/134.9266*134.9266
=1.500

Current CPI (Mar. 2025) = 134.9266.

TG Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 2.187 100.684 2.931
201509 2.215 100.392 2.977
201512 1.879 99.792 2.541
201603 1.654 100.470 2.221
201606 1.445 101.688 1.917
201609 1.037 101.861 1.374
201612 0.632 101.863 0.837
201703 1.513 102.862 1.985
201706 1.145 103.349 1.495
201709 1.126 104.136 1.459
201712 0.916 104.011 1.188
201803 1.106 105.290 1.417
201806 1.229 106.317 1.560
201809 0.865 106.507 1.096
201812 0.287 105.998 0.365
201903 0.217 107.251 0.273
201906 0.141 108.070 0.176
201909 -0.267 108.329 -0.333
201912 0.353 108.420 0.439
202003 -0.012 108.902 -0.015
202006 1.534 108.767 1.903
202009 1.324 109.815 1.627
202012 3.694 109.897 4.535
202103 3.147 111.754 3.800
202106 2.682 114.631 3.157
202109 2.179 115.734 2.540
202112 1.656 117.630 1.900
202203 1.179 121.301 1.311
202206 0.889 125.017 0.959
202209 0.691 125.227 0.745
202212 0.400 125.222 0.431
202303 0.184 127.348 0.195
202306 0.268 128.729 0.281
202309 1.088 129.860 1.130
202312 1.060 129.419 1.105
202403 1.036 131.776 1.061
202406 1.147 132.554 1.168
202409 1.234 133.029 1.252
202412 1.427 133.157 1.446
202503 1.500 134.927 1.500

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


TG Therapeutics  (LTS:0VGI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

TG Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=37.50/1.38
=27.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of TG Therapeutics was 30.56. The lowest was 1.52. And the median was 10.68.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


TG Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

TG Therapeutics Headlines

No Headlines